Choose your preferred way to stay informed of new case launches and settlement deadlines
On July 8, 2024, HilleVax was the subject of a Fierce Biotech article. According to the article, "HilleVax's stock took a nosedive after the vaccine biotech's sole clinical-stage candidate failed a phase 2b trial in norovirus-related acute gastroenteritis (AGE)." The article continues, "The virus-like particle-based vaccine, dubbed HIL-214, missed all primary and secondary endpoints of the NEST-IN1 study of more than 2,800 infants aged about five months of age in the U.S. and Latin America."
In order to be eligible to join the HLVX class action lawsuit, you must have incurred a loss on shares of HilleVax purchased during the class period listed above.
TOP
